Participating Organization(s): | National Institutes of Health (NIH) |
Components of Participating Organizations: | |
Funding Opportunity Title: | Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC -CCs) (U01) |
Activity Code: | U01 Research Project Cooperative Agreements |
Announcement Type: | New |
Related Notices: | September 26, 2019 - This RFA has been reissued as RFA-DK-19-009. |
Funding Opportunity Announcement (FOA) Number: | |
Companion Funding Opportunity: | RFA-DK-14-028, U01 Research Project Cooperative Agreements |
Number of Applications; | |
Catalog of Federal Domestic Assistance (CFDA) Number(s): | 93.847, 93.393 and 93.399 |
Funding Opportunity Purpose: |
This Funding Opportunity Announcement (FOA) invites U01 applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.
The Consortium will form multi-disciplinary teams composed of members from the CCs and CDMC to undertake a comprehensive clinical, epidemiological, and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM, and the diabetes/pancreatic cancer association. The teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients.
Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-14-028 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CSCPDPC-CDMC) (U01)".
To achieve the goal of a comprehensive characterization of evolving chronic pancreatitis and pancreatic cancer, each CC should include researchers and clinicians with multi-disciplinary expertise. Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.
In addition, a major collaborative effort within the Consortium will be the establishment of an annotated repository of biospecimens (blood, pancreatic and duodenal juice, stools, and when feasible pancreatic tissue) to allow for the identification and validation of biomarkers for risk stratification and/or early detection.
Comments